- Investing Ideas
- Australian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Australian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
5
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
5 companies
CSL
Market Cap: AU$60.1b
Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$122.89
7D
0.9%
1Y
-49.0%
Telix Pharmaceuticals
Market Cap: AU$5.7b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$16.27
7D
-3.6%
1Y
-32.5%
Mesoblast
Market Cap: AU$2.7b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.24
7D
8.7%
1Y
35.3%
Aroa Biosurgery
Market Cap: AU$202.4m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.59
7D
3.5%
1Y
2.6%
Avecho Biotechnology
Market Cap: AU$84.3m
A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India.
AVE
AU$0.022
7D
-4.3%
1Y
388.9%